CIRCA THERAPEUTICS

Sparking the next revolution in precise protein degradation

CIRCA Therapeutics is developing ligand-directed targeted protein degraders to address high-value oncology targets. We combine computational design, medicinal chemistry, and translational biology to advance differentiated candidates.

• What we do
• Our approach
• Pipeline
• Team
• Contact

• Twitter
• Facebook
• Instagram
• Email

© circa

What we do

We develop ligand-directed targeted protein degraders for oncology programs.Bullets:Computational design to inform warhead and linker selection.Medicinal chemistry to synthesize and optimize candidate series.In vitro biology and mechanistic assays to validate degradation and selectivity.Translational strategy to prioritize programs with clear path to development.

• Back

Our approach

Our approach integrates design, chemistry, and biology to advance ligand-directed targeted protein degraders.Steps (4 bullets):Design – Computational modeling to prioritize warheads, linkers, and binding hypotheses.Build – Rapid synthesis and iterative optimization of candidate series.Validate – In vitro degradation and mechanistic assays to confirm MoA and selectivity.Advance – Program prioritization with defined milestones toward lead selection.We focus on rigorous data packages and reproducible decision-making at each stage.

• Back